N-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids.

A. Tricker
{"title":"N-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids.","authors":"A. Tricker","doi":"10.1097/00008469-199706000-00003","DOIUrl":null,"url":null,"abstract":"Based on recent analytical data, total human exogenous exposure to N-nitrosamines is estimated to be 1.10 mumol/day; the major exposure sources are the diet (0.79 mumol/may, 80-120 micrograms/day; 72%), occupational exposure (0.15-0.30 mumol/day; 25%), cigarette smoking (0.02 mumol/day, 3.4 micrograms/day; 2%), and miscellaneous minor sources, including pharmaceutical products, cosmetics, indoor and outdoor air (0.001 mumol/day, 0.1 micrograms/day; 1%). Excretion of apparent total N-nitroso compounds (ATNC) in healthy adults is estimated to be 1.30 +/- 1.05 mumol/day in urine and between 1.56 +/- 1.56 and 3.17 +/- 2.58 mumol/day in faeces. The excretion of volatile N-nitrosamines (N-nitrosodimethylamine), and N-nitrosamine acids and their derivatives (N-nitrososarcosine, N-nitrosoproline, N-nitrosothiazolidine-4-carboxylic acid and N-nitroso-2-methylthiazoline-4-carboxylic acid) accounts for approximately 0.03% and 16.0% of urinary ATNC, respectively. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol and its O-glucuronide conjugate, two metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone present in urine of smokers, account for 0.2% of the urinary ATNC response; < 1.5 of the excretion of currently identified N-nitroso compounds in urine. The remaining N-nitroso compounds excreted in urine and those present in faeces are still unidentified. A crude mass balance between exogenous exposure and excretion in urine and faeces indicates that 45-75% of the total human exposure to N-nitroso compounds results through in vivo formation.","PeriodicalId":11950,"journal":{"name":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1997-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"230","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00008469-199706000-00003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 230

Abstract

Based on recent analytical data, total human exogenous exposure to N-nitrosamines is estimated to be 1.10 mumol/day; the major exposure sources are the diet (0.79 mumol/may, 80-120 micrograms/day; 72%), occupational exposure (0.15-0.30 mumol/day; 25%), cigarette smoking (0.02 mumol/day, 3.4 micrograms/day; 2%), and miscellaneous minor sources, including pharmaceutical products, cosmetics, indoor and outdoor air (0.001 mumol/day, 0.1 micrograms/day; 1%). Excretion of apparent total N-nitroso compounds (ATNC) in healthy adults is estimated to be 1.30 +/- 1.05 mumol/day in urine and between 1.56 +/- 1.56 and 3.17 +/- 2.58 mumol/day in faeces. The excretion of volatile N-nitrosamines (N-nitrosodimethylamine), and N-nitrosamine acids and their derivatives (N-nitrososarcosine, N-nitrosoproline, N-nitrosothiazolidine-4-carboxylic acid and N-nitroso-2-methylthiazoline-4-carboxylic acid) accounts for approximately 0.03% and 16.0% of urinary ATNC, respectively. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol and its O-glucuronide conjugate, two metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone present in urine of smokers, account for 0.2% of the urinary ATNC response; < 1.5 of the excretion of currently identified N-nitroso compounds in urine. The remaining N-nitroso compounds excreted in urine and those present in faeces are still unidentified. A crude mass balance between exogenous exposure and excretion in urine and faeces indicates that 45-75% of the total human exposure to N-nitroso compounds results through in vivo formation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
n -亚硝基化合物与人:接触来源、内源性形成和在体液中的发生。
根据最近的分析数据,估计人类对n -亚硝胺的总外源性暴露量为1.10毫摩尔/天;主要暴露源为饮食(0.79 μ mol/ 5, 80-120微克/天;72%),职业暴露(0.15-0.30 μ mol/天;25%),吸烟(0.02毫摩尔/天,3.4微克/天;2%),以及其他次要来源,包括药品、化妆品、室内外空气(0.001 μ mol/天,0.1微克/天;1%)。据估计,健康成人尿液中总n -亚硝基化合物(ATNC)的排泄量为1.30 +/- 1.05 μ mol/天,粪便中总n -亚硝基化合物(ATNC)的排泄量为1.56 +/- 1.56至3.17 +/- 2.58 μ mol/天。挥发性n -亚硝胺(n -亚硝基二甲胺)和n -亚硝胺酸及其衍生物(n -亚硝基肌氨酸、n -亚硝基脯氨酸、n -亚硝基噻唑烷-4-羧酸和n -亚硝基-2-甲基噻唑啉-4-羧酸)的排泄量分别约占尿ATNC的0.03%和16.0%。吸烟者尿液中存在4-(甲基亚硝胺)-1-(3-吡啶基)-1-丁醇及其o -葡糖醛酸缀合物4-(甲基亚硝胺)-1-(3-吡啶基)-1-丁酮的两种代谢物,占尿ATNC反应的0.2%;尿中目前确定的n -亚硝基化合物排泄量< 1.5。其余的n -亚硝基化合物排泄尿液和存在于粪便仍未确定。外源性暴露与尿液和粪便排泄之间的粗质量平衡表明,人类对n -亚硝基化合物的总暴露中有45-75%是通过体内形成的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The PROPHET project paves the way for personalized prevention in the future healthcare. Prostate cancer burden in major BRICS countries, 1990-2019: findings from the 2019 global burden of disease study. Cancer mortality predictions for 2024 in selected Asian countries and Australia with focus on stomach cancer. Non-contrast MRI and post-mastectomy silicone breast implant rupture: preventing false positive diagnoses. Comment to: Inequalities in adherence to cervical cancer screening in Portugal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1